ESMO 2022 | VISION: association between PSA decline & clinical outcomes in patients with mCRPC

Andrew Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, discusses findings of a post-hoc exploratory analysis of the VISION trial (NCT03511664) which aimed to evaluate the associations between prostate-specific antigen (PSA) decline and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.